{"id":746483,"date":"2023-04-11T07:06:56","date_gmt":"2023-04-11T11:06:56","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/abstract-evaluating-allaritys-drp-companion-diagnostic-for-cisplatin-accepted-at-2023-asco-annual-meeting\/"},"modified":"2023-04-11T07:06:56","modified_gmt":"2023-04-11T11:06:56","slug":"abstract-evaluating-allaritys-drp-companion-diagnostic-for-cisplatin-accepted-at-2023-asco-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/abstract-evaluating-allaritys-drp-companion-diagnostic-for-cisplatin-accepted-at-2023-asco-annual-meeting\/","title":{"rendered":"Abstract Evaluating Allarity\u2019s DRP\u00ae Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting"},"content":{"rendered":"
\n

\n
\n FOR IMMEDIATE RELEASE<\/u>
\n <\/strong>\n <\/p>\n

\n Abstract Evaluating Allarity\u2019s DRP<\/strong>
\n \u00ae<\/strong>
\n Companion Diagnostic<\/strong>
\n for Cisplatin<\/strong>
\n Accepted at 2023 ASCO Annual Meeting<\/strong>\n <\/p>\n

\n Poster presentation focused on a Phase 2 Clinical Study Evaluating the Utility of a DRP<\/em>
\n
\n \u00ae<\/em>
\n <\/sup>
\n Companion Diagnostic for<\/em>
\n Cisplatin Response in<\/em>
\n Certain Breast Cancer Patients<\/em>\n <\/p>\n

\n Boston, MA<\/strong> (April 11, 2023) \u2014 Allarity Therapeutics, Inc. (\u201cAllarity\u201d or the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP\u00ae<\/sup> companion diagnostics for personalized cancer care, today announced that an abstract on the Company\u2019s proprietary DRP\u00ae<\/sup> technology has been accepted for a poster presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.<\/p>\n

Researchers will present the data at the ASCO meeting taking place June 2-6 online and in person at the McCormick Place in Chicago. The poster shows the final data from a phase 2 study evaluating the ability of the DRP\u00ae<\/sup> companion diagnostic for cisplatin to prospectively identify patients with metastatic breast cancer that are likely to respond to treatment with LiPlaCis\u00ae<\/sup>, a targeted liposomal formulation of cisplatin. Allarity conducted the study in collaboration with investigators at hospitals in Denmark, as well as its CRO Smerud Medical Research International AS. The LiPlaCis program is currently licensed to Chosa Oncology AB for further clinical development.<\/p>\n

The poster presentation details are as follows:<\/p>\n

\n Poster Title<\/strong>: \u201cPredictive biomarker for cisplatin in prospective phase 2 of liposomal cisplatin in metastatic breast cancer.\u201d
Authors:<\/strong> Nielsen, D., Jakobsen, E,H., Langkjer, S.T., Danoe, H., Balslev, E., Knoop, A., \u2026 Lassen, U.N.
Abstract Number<\/strong>: 3130
Session Title<\/strong>: Developmental Therapeutics\u2014Molecularly Targeted Agents and Tumor Biology
Date and Time<\/strong>: 6\/3\/2023, 8:00 AM-11:00 AM local time<\/p>\n

ASCO will publish the official abstracts on its meeting website in advance of the ASCO Annual Meeting at 5:00 p.m. ET on Thursday, May 25, 2023.
About Allarity Therapeutics<\/strong>\u00a0<\/strong>
Allarity Therapeutics, Inc. (Nasdaq: ALLR) develops drugs for personalized treatment of cancer guided by its proprietary and highly validated companion diagnostic technology, the DRP\u00ae<\/sup>\u00a0platform. The Company has a mature portfolio of three drug candidates: stenoparib, a PARP inhibitor in Phase 2 development for ovarian cancer, and in Phase 1 development for advanced solid tumors in a combination treatment with dovitinib, a pan-tyrosine kinase inhibitor (pan-TKI) that has previously been developed through Phase 3 in renal cancer; and IXEMPRA\u00ae<\/sup>\u00a0(Ixabepilone), a microtubule inhibitor approved in the U.S. and marketed by R-PHARM U.S. for the treatment of second-line metastatic breast cancer, currently in Phase 2 development in Europe for the same indication. Additionally, the Company has rights in two secondary assets: 2X-111, a liposomal formulation of doxorubicin for metastatic breast cancer and\/or glioblastoma multiforme (GBM), which is the subject of discussions for a restructured out-license to Smerud Medical Research International AS; and LiPlaCis\u00ae<\/sup>, a liposomal formulation of cisplatin and its accompanying DRP\u00ae<\/sup>, being developed via a partnership with Chosa Oncology AB for late-stage metastatic breast cancer. The Company is headquartered in the United States and maintains an R&D facility in Hoersholm, Denmark. For more information, please visit the Company\u2019s website at\u00a0www.Allarity.com<\/a>.
About the Drug Response Predictor \u2013 DRP<\/strong>\u00a0\u00ae<\/strong>\u00a0Companion Diagnostic<\/strong>\u00a0<\/strong>
Allarity uses its drug specific DRP to select those patients who, by the genetic signature of their cancer, are found to have a high likelihood of responding to the specific drug. By screening patients before treatment, and only treating those patients with a sufficiently high DRP score, the therapeutic response rate can be significantly increased. The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines combined with clinical tumor biology filters and prior clinical trial outcomes. DRP is based on messenger RNA from patient biopsies. The DRP platform has proven its ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients in 37 out of 47 clinical studies that were examined (both retrospective and prospective), including ongoing, prospective Phase 2 trials of Stenoparib and IXEMPRA\u00ae<\/sup>. The DRP platform, which can be used in all cancer types and is patented for more than 70 anti-cancer drugs, has been extensively published in peer reviewed literature.
Follow Allarity on<\/strong>\u00a0<\/strong>Social Media<\/strong><\/p>\n

Facebook:\u00a0https:\/\/www.facebook.com\/AllarityTx<\/a><\/p>\n

LinkedIn:\u00a0https:\/\/www.linkedin.com\/company\/allaritytx\/<\/a><\/p>\n

Twitter:\u00a0https:\/\/twitter.com\/allaritytx<\/a><\/p>\n

\n Forward-Looking Statements<\/strong>
\n \u00a0<\/strong>
\n
\n This press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide Allarity\u2019s current expectations or forecasts of future events. The words \u201canticipates,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredicts,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201cwould\u201d and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements related to the expected availability of capital to fund its anticipated clinical trials, statements related to advancing dovitinib in combination with stenoparib or another therapeutic candidate or other approved drug, any statements related to ongoing clinical trials for stenoparib as a monotherapy or in combination with another therapeutic candidate for the treatment of advanced ovarian cancer, or ongoing clinical trials (in Europe) for IXEMPRA<\/em>\u00a0\u00ae<\/sup>\u00a0for the treatment of metastatic breast cancer, statements relating to the effectiveness of the Company\u2019s DRP<\/em>\u00a0\u00ae<\/sup>\u00a0companion diagnostics platform in predicting whether a particular patient is likely to respond to a specific drug, and statements related to the Company\u2019s ability to regain compliance with the Nasdaq Listing Rule. Any forward-looking statements in this press release are based on management\u2019s current expectations of future events and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company is not able to raise sufficient capital to support its current and anticipated clinical trials,\u00a0the risk that results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive reviews of the data, and as more patient data become available, the risk that results of a clinical study are subject to interpretation and additional analyses may be needed and\/or may contradict such results, the receipt of regulatory approval for dovitinib or any of our<\/em>\u00a0<\/em>other therapeutic candidates or, if approved, the successful commercialization of such products, the risk of cessation or delay of any of the ongoing or planned clinical trials and\/or our development of our product candidates, the risk that the results of previously conducted studies will not be repeated or observed in ongoing or future studies involving our therapeutic candidates, and the risk that the current COVID-19 pandemic will impact the Company\u2019s current and future clinical trials and the timing of the Company\u2019s preclinical studies and other operations. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled \u201cRisk Factors\u201d in our Form 10-K annual report\u00a0on file with the\u00a0Securities and Exchange Commission, available at the Securities and Exchange Commission\u2019s website at\u00a0<\/em>\u00a0www.sec.gov<\/em><\/a>\u00a0<\/a>, and as well as discussions of potential risks, uncertainties and other important factors in the Company\u2019s subsequent filings with the\u00a0Securities and Exchange <\/em>Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.<\/em><\/p>\n

###<\/p>\n

U.S. Media Contact:
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Mike Beyer
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Sam Brown, Inc.
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0+1 (312) 961-2502
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0mikebeyer@sambrown.com<\/a>
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0
EU Media Contact:
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Thomas Pedersen
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Carrotize PR & Communications
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0+45 6062 9390
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0tsp@carrotize.com<\/a><\/p>\n<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

FOR IMMEDIATE RELEASE Abstract Evaluating Allarity\u2019s DRP \u00ae Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting Poster presentation focused on a Phase 2 Clinical Study Evaluating the Utility of a DRP \u00ae Companion Diagnostic for Cisplatin Response in Certain Breast Cancer Patients Boston, MA (April 11, 2023) \u2014 Allarity Therapeutics, Inc. (\u201cAllarity\u201d or the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP\u00ae companion diagnostics for personalized cancer care, today announced that an abstract on the Company\u2019s proprietary DRP\u00ae technology has been accepted for a poster presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. Researchers will present the data at the ASCO meeting taking place June 2-6 online and in … <\/p>\n

Continue reading “Abstract Evaluating Allarity\u2019s DRP\u00ae Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-746483","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAbstract Evaluating Allarity\u2019s DRP\u00ae Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/abstract-evaluating-allaritys-drp-companion-diagnostic-for-cisplatin-accepted-at-2023-asco-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Abstract Evaluating Allarity\u2019s DRP\u00ae Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"FOR IMMEDIATE RELEASE Abstract Evaluating Allarity\u2019s DRP \u00ae Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting Poster presentation focused on a Phase 2 Clinical Study Evaluating the Utility of a DRP \u00ae Companion Diagnostic for Cisplatin Response in Certain Breast Cancer Patients Boston, MA (April 11, 2023) \u2014 Allarity Therapeutics, Inc. (\u201cAllarity\u201d or the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP\u00ae companion diagnostics for personalized cancer care, today announced that an abstract on the Company\u2019s proprietary DRP\u00ae technology has been accepted for a poster presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. Researchers will present the data at the ASCO meeting taking place June 2-6 online and in … Continue reading "Abstract Evaluating Allarity\u2019s DRP\u00ae Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/abstract-evaluating-allaritys-drp-companion-diagnostic-for-cisplatin-accepted-at-2023-asco-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-11T11:06:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgwMzE3NCM0MDE1MjM3ODEjMjAwMTEwNQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abstract-evaluating-allaritys-drp-companion-diagnostic-for-cisplatin-accepted-at-2023-asco-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abstract-evaluating-allaritys-drp-companion-diagnostic-for-cisplatin-accepted-at-2023-asco-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Abstract Evaluating Allarity\u2019s DRP\u00ae Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting\",\"datePublished\":\"2023-04-11T11:06:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abstract-evaluating-allaritys-drp-companion-diagnostic-for-cisplatin-accepted-at-2023-asco-annual-meeting\\\/\"},\"wordCount\":1279,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abstract-evaluating-allaritys-drp-companion-diagnostic-for-cisplatin-accepted-at-2023-asco-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDgwMzE3NCM0MDE1MjM3ODEjMjAwMTEwNQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abstract-evaluating-allaritys-drp-companion-diagnostic-for-cisplatin-accepted-at-2023-asco-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abstract-evaluating-allaritys-drp-companion-diagnostic-for-cisplatin-accepted-at-2023-asco-annual-meeting\\\/\",\"name\":\"Abstract Evaluating Allarity\u2019s DRP\u00ae Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abstract-evaluating-allaritys-drp-companion-diagnostic-for-cisplatin-accepted-at-2023-asco-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abstract-evaluating-allaritys-drp-companion-diagnostic-for-cisplatin-accepted-at-2023-asco-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDgwMzE3NCM0MDE1MjM3ODEjMjAwMTEwNQ==\",\"datePublished\":\"2023-04-11T11:06:56+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abstract-evaluating-allaritys-drp-companion-diagnostic-for-cisplatin-accepted-at-2023-asco-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abstract-evaluating-allaritys-drp-companion-diagnostic-for-cisplatin-accepted-at-2023-asco-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abstract-evaluating-allaritys-drp-companion-diagnostic-for-cisplatin-accepted-at-2023-asco-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDgwMzE3NCM0MDE1MjM3ODEjMjAwMTEwNQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDgwMzE3NCM0MDE1MjM3ODEjMjAwMTEwNQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abstract-evaluating-allaritys-drp-companion-diagnostic-for-cisplatin-accepted-at-2023-asco-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Abstract Evaluating Allarity\u2019s DRP\u00ae Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Abstract Evaluating Allarity\u2019s DRP\u00ae Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/abstract-evaluating-allaritys-drp-companion-diagnostic-for-cisplatin-accepted-at-2023-asco-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Abstract Evaluating Allarity\u2019s DRP\u00ae Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting - Market Newsdesk","og_description":"FOR IMMEDIATE RELEASE Abstract Evaluating Allarity\u2019s DRP \u00ae Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting Poster presentation focused on a Phase 2 Clinical Study Evaluating the Utility of a DRP \u00ae Companion Diagnostic for Cisplatin Response in Certain Breast Cancer Patients Boston, MA (April 11, 2023) \u2014 Allarity Therapeutics, Inc. (\u201cAllarity\u201d or the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP\u00ae companion diagnostics for personalized cancer care, today announced that an abstract on the Company\u2019s proprietary DRP\u00ae technology has been accepted for a poster presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. Researchers will present the data at the ASCO meeting taking place June 2-6 online and in … Continue reading \"Abstract Evaluating Allarity\u2019s DRP\u00ae Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/abstract-evaluating-allaritys-drp-companion-diagnostic-for-cisplatin-accepted-at-2023-asco-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-11T11:06:56+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgwMzE3NCM0MDE1MjM3ODEjMjAwMTEwNQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abstract-evaluating-allaritys-drp-companion-diagnostic-for-cisplatin-accepted-at-2023-asco-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abstract-evaluating-allaritys-drp-companion-diagnostic-for-cisplatin-accepted-at-2023-asco-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Abstract Evaluating Allarity\u2019s DRP\u00ae Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting","datePublished":"2023-04-11T11:06:56+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abstract-evaluating-allaritys-drp-companion-diagnostic-for-cisplatin-accepted-at-2023-asco-annual-meeting\/"},"wordCount":1279,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abstract-evaluating-allaritys-drp-companion-diagnostic-for-cisplatin-accepted-at-2023-asco-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgwMzE3NCM0MDE1MjM3ODEjMjAwMTEwNQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abstract-evaluating-allaritys-drp-companion-diagnostic-for-cisplatin-accepted-at-2023-asco-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/abstract-evaluating-allaritys-drp-companion-diagnostic-for-cisplatin-accepted-at-2023-asco-annual-meeting\/","name":"Abstract Evaluating Allarity\u2019s DRP\u00ae Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abstract-evaluating-allaritys-drp-companion-diagnostic-for-cisplatin-accepted-at-2023-asco-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abstract-evaluating-allaritys-drp-companion-diagnostic-for-cisplatin-accepted-at-2023-asco-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgwMzE3NCM0MDE1MjM3ODEjMjAwMTEwNQ==","datePublished":"2023-04-11T11:06:56+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abstract-evaluating-allaritys-drp-companion-diagnostic-for-cisplatin-accepted-at-2023-asco-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/abstract-evaluating-allaritys-drp-companion-diagnostic-for-cisplatin-accepted-at-2023-asco-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abstract-evaluating-allaritys-drp-companion-diagnostic-for-cisplatin-accepted-at-2023-asco-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgwMzE3NCM0MDE1MjM3ODEjMjAwMTEwNQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgwMzE3NCM0MDE1MjM3ODEjMjAwMTEwNQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abstract-evaluating-allaritys-drp-companion-diagnostic-for-cisplatin-accepted-at-2023-asco-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Abstract Evaluating Allarity\u2019s DRP\u00ae Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/746483","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=746483"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/746483\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=746483"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=746483"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=746483"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}